<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394652</url>
  </required_header>
  <id_info>
    <org_study_id>CXMET1</org_study_id>
    <nct_id>NCT02394652</nct_id>
  </id_info>
  <brief_title>The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial</brief_title>
  <official_title>The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation&#xD;
      (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation&#xD;
      treatment. Hypoxia-modifying therapies improve survival, but existing therapies are&#xD;
      impractical and/or toxic. Metformin, a non-toxic drug for diabetes, has been shown to&#xD;
      decrease tumor hypoxia in animal studies and its use is associated with better survival in&#xD;
      diabetic cancer patients. It is hypothesized that metformin may decrease cervical tumor&#xD;
      hypoxia and thereby improve tumor response to radiation and survival in patients with locally&#xD;
      advanced cervix cancer.&#xD;
&#xD;
      This is a randomized, multicenter phase II study of standard chemoradiation in combination&#xD;
      with metformin versus standard chemoradiation alone in women with locally advanced cervix&#xD;
      cancer. Women randomized to the metformin group will take metformin starting 1 week prior to&#xD;
      standard chemoradiation and throughout the duration of external radiation treatment. Tumor&#xD;
      hypoxia will be measured by a special X-ray test called positron emission test (PET)&#xD;
      performed with a hypoxia dye called FAZA. The main purpose of this study is to see if&#xD;
      metformin decreases tumor hypoxia measured on FAZA-PET; information about response and side&#xD;
      effects will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Actual">January 12, 2021</completion_date>
  <primary_completion_date type="Actual">January 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Change in fractional hypoxic volume of the tumor on FAZA-PET scan before and after 1 week of metformin.</measure>
    <time_frame>About 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late gastrointestinal and genitourinary toxicities following metformin and chemoradiation.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of metformin on endogenous hypoxia and other markers.</measure>
    <time_frame>About 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of response to metformin.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Carcinoma, Adenosquamous</condition>
  <arm_group>
    <arm_group_label>Experimental: Metformin with Standard Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.&#xD;
Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.&#xD;
FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.&#xD;
FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin is an antidiabetic agent given orally.</description>
    <arm_group_label>Experimental: Metformin with Standard Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is an antineoplastic agent given intravenously.</description>
    <arm_group_label>Experimental: Metformin with Standard Chemoradiation</arm_group_label>
    <arm_group_label>Standard Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAZA</intervention_name>
    <description>FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.</description>
    <arm_group_label>Experimental: Metformin with Standard Chemoradiation</arm_group_label>
    <arm_group_label>Standard Chemoradiation</arm_group_label>
    <other_name>18F-Fluoroazomycin arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous&#xD;
             carcinoma of the cervix, FIGO stage IB2-IVA&#xD;
&#xD;
          -  Planned for radical radiotherapy and concurrent cisplatin chemotherapy.&#xD;
&#xD;
          -  Able to receive weekly cisplatin.&#xD;
&#xD;
          -  No prior anticancer treatment for cervical cancer&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
          -  Able to take oral medications.&#xD;
&#xD;
          -  Ability to understand and willing to sign the consent form&#xD;
&#xD;
          -  Willing to undergo biopsies of cervical tumor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Receiving any other investigational agents concurrently or within 4 weeks.&#xD;
&#xD;
          -  Known diabetes mellitus.&#xD;
&#xD;
          -  Currently taking metformin, sulfonylureas, thiazolidinediones or insulin.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to metformin or cisplatin.&#xD;
&#xD;
          -  Any condition associated with increased risk of metformin-associated lactic acidosis&#xD;
&#xD;
          -  Uncontrolled inter-current illness&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  History of another invasive malignancy, except for non-melanoma skin cancer or tumors&#xD;
             curatively treated with no evidence of disease for &gt;=5 years.&#xD;
&#xD;
          -  Known HIV-positive&#xD;
&#xD;
          -  History of bowel obstruction or malabsorption syndromes&#xD;
&#xD;
          -  History of active clinically significant bleeding&#xD;
&#xD;
          -  Contraindications to radiotherapy&#xD;
&#xD;
          -  Taking drug disulfiram (antabuse).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De L'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Fluoroazomycin arabinoside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

